secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-03-12T23:59:59+00:00
Accession:  0001171843-25-001410
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose provides TUS+VEN+AZA triplet clinical update and 2025 milestones
-----------------------------------------------------------------------

- 40mg TUS+VEN+AZA triplet achieved CRs in FLT3-WT and TP53-mutated newly diagnosed AML; no DLTs.
- 80mg TUS dose cohort in TUS+VEN+AZA triplet is currently enrolling.
- Hanmi collaboration expected Q2 2025; $10M advance converting to common stock.
- Raised approx. $37M in 2024; capital structure: 2.14M shares O/S, 1.27M warrants.
- Planned data releases at EHA 2025 and ASH 2025; dose selection for Ph2/3 pivotal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184325001410/0001171843-25-001410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184325001410/f8k_031125.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-001410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer